-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IXEsxmlTKvZgkeaC5fWhoXmnhbpyPuUx6UUL6ijAEmZXzR8EuGPqBKbjXWyrS0US
 Kkh7kwxgiixQooRCTdUJGA==

<SEC-DOCUMENT>0000950134-04-020044.txt : 20041230
<SEC-HEADER>0000950134-04-020044.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041230170800
ACCESSION NUMBER:		0000950134-04-020044
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041224
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOTIME INC
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		041234699

	BUSINESS ADDRESS:	
		STREET 1:		935 PARDEE ST
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108459535

	MAIL ADDRESS:	
		STREET 1:		935 PARDEE STREET
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f04328e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 14pt">SECURITIES AND EXCHANGE COMMISSION

<P align="center" style="font-size: 12pt">Washington, D.C. 20549

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 12pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>


<P align="left" style="font-size: 10pt">Date of Report (date of earliest event reported): December&nbsp;24, 2004.



<P align="center" style="font-size: 10pt"><B>BioTime, Inc.</B>


<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-12830</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94-3127919</B></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>935 Pardee Street<BR>
Berkeley, California 94710</B>


<DIV align="center" style="font-size: 10pt">(Address of principal executive offices)</DIV>



<P align="center" style="font-size: 10pt"><B>(510)&nbsp;845-9535</B>


<DIV align="center" style="font-size: 10pt">(Registrant&#146;s telephone number, including area code)</DIV>


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17
CFR 230.425)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
  Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;1.01 Entry Into a Material Definitive Agreement</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002"> SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="f04328exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>







<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to those
discussed in this report and in BioTime&#146;s Annual Report on </I><I>Form 10-K</I><I> filed with
the Securities and Exchange Commission. Words such as &#147;expects,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;anticipates,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; and
similar expressions identify forward-looking statements.</I>


<P align="left" style="font-size: 10pt"><B>Section&nbsp;1-Registrant&#146;s Business Operations</B>


<!-- link1 "Item&nbsp;1.01 Entry Into a Material Definitive Agreement" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;1.01 Entry Into a Material Definitive Agreement</B>


<P align="left" style="font-size: 10pt">On December&nbsp;24, 2004, BioTime, Inc. and Summit Pharmaceuticals International
Corporation (&#147;Summit&#148;) entered into an agreement to develop Hextend and
PentaLyte for the Japanese market. Hextend and PentaLyte are physiologically
balanced blood plasma volume expanders designed for the treatment of
hypovolemia. Hypovolemia is a condition caused by low blood volume, often from
blood loss during surgery or from injury. Plasma volume expanders maintain
circulatory system fluid volume and blood pressure and keep vital organs
perfused during surgery. Hextend and PentaLyte are similar formulations,
except that PentaLyte contains a lower molecular weight hydroxyethyl starch
than Hextend, and is more quickly metabolized. PentaLyte is designed for use
when shorter lasting volume expansion is desirable.


<P align="left" style="font-size: 10pt">Under the terms of the agreement, Summit will apply for regulatory approval to
manufacture and market Hextend and PentaLyte in Japan for use at body
temperatures above 12 Centigrade. Summit will begin by preparing a development
plan for Hextend. Summit will fund all laboratory, preclinical and clinical
testing and developmental activities regarding the products, and will pay all
application filing and similar fees for purposes of obtaining and maintaining
regulatory approvals in Japan. Summit will not be obligated to begin to seek
regulatory approval for PentaLyte until BioTime completes its Phase II clinical
trial of PentaLyte in the United States and makes the results available to
Summit. BioTime&#146;s Phase II clinical trial is now beginning and will take place
at Duke University Medical Center.


<P align="left" style="font-size: 10pt">Under the Agreement, Summit will make the following payments to BioTime:



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$300,000 within ten days after execution of the agreement;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$450,000 by April&nbsp;15, 2005; and</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$150,000 by October&nbsp;31, 2005.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>

<P align="left" style="font-size: 10pt">A portion of the cash payments will be a partial reimbursement of BioTime&#146;s
development costs of Hextend and a portion will be a partial reimbursement of
BioTime&#146;s development costs of PentaLyte.


<P align="left" style="font-size: 10pt">Within ten days after BioTime approves Summit&#146;s development plan for Hextend,
BioTime will pay Summit a one-time fee of $130,000 for Summit&#146;s services in
preparing the development plan.


<P align="left" style="font-size: 10pt">BioTime and Summit do not plan to manufacture and market Hextend and PentaLyte
themselves. Instead, they will seek to license manufacturing and marketing
rights to a third party such as a pharmaceutical company.


<P align="left" style="font-size: 10pt">When Hextend and PentaLyte are licensed and sold in Japan, the revenues from
licensing fees, royalties, and net sales, and any other payments made for
co-development, manufacturing, or marking rights, will be shared between
BioTime and Summit as follows: 40% to BioTime and 60% to Summit. Net sales
means the gross revenues from the sale of a product, less rebates, discounts,
returns, transportation costs, sales taxes and import/export duties.


<P align="left" style="font-size: 10pt">BioTime will pay to Summit 8% of all net royalties actually received by BioTime
from the sale of PentaLyte in the United States plus 8% of any license fees
that BioTime receives in consideration of granting a license to develop,
manufacture and market PentaLyte in the United States. Net royalties means
royalty payments received during a calendar year, minus the following costs and
expenses incurred during such calendar year: (a)&nbsp;all taxes assessed (other than
taxes determined with reference to BioTime net income) and credits given or
owed by BioTime in connection with the receipt of royalties on the sale of
PentaLyte in the United States, and (b)&nbsp;all fees and expenses payable by
BioTime to the United States Food and Drug Administration (directly or as a
reimbursement of any licensee) with respect to PentaLyte. In the case of
license fees received from Hospira, Inc. based upon the combined sale of
PentaLyte and Hextend, the portion of such license fee that will be deemed to
be paid on account of the sale of PentaLyte will be determined by multiplying
the total license fee paid by a fraction, the numerator of which will be the
total net sales of PentaLyte in the United States for the applicable period and
the denominator of which shall be the total net sales of Hextend and PentaLyte
in the United States for the same period.


<P align="left" style="font-size: 10pt">Either BioTime or Summit may terminate the agreement as follows:



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By giving to the other party 60&nbsp;days prior written notice
following the bankruptcy or the insolvency of the other party; or</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the breach of any material provision of the agreement by
the other party if the breach is not cured within 60&nbsp;days after
written notice thereof to the party in default.</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt">BioTime may terminate the agreement upon 60&nbsp;days prior written notice at any
time following Summit&#146;s failure to use diligent efforts to achieve any one of

the following milestones: (A)
submitting to BioTime for approval a development plan that is substantially
complete in all material respects within six months after the signing of the
agreement, (B)&nbsp;initiating and conducting to



<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">completion clinical studies needed
for regulatory approval of either Hextend or PentaLyte in accordance with the
timetable included in the development plan approved by BioTime; or (C)
obtaining regulatory approval of either Hextend or PentaLyte after the clinical
studies are complete.


<P align="left" style="font-size: 10pt">Summit may terminate the agreement at any time upon ninety 90&nbsp;days prior
written notice to BioTime if Summit determines that it no longer wishes to
pursue obtaining regulatory approval of Hextend and PentaLyte.


<P align="left" style="font-size: 10pt">If BioTime becomes bankrupt or insolvent or breaches a material provision of
the agreement such that Summit would have the right to terminate the agreement,
Summit may elect to keep the agreement in effect, and in lieu of any other
remedy that Summit might have (1)&nbsp;if any of the cash installment payments are
not yet payable Summit will be exempted from making those payments, and (2)
BioTime&#146;s 40% share of revenues will be reduced to 20%.


<P align="left" style="font-size: 10pt">The preceding discussion of the agreement is a summary only, does not purport
to describe in full all provisions of the agreement, and is qualified in all
respects by the full text of the agreement, a copy of which has been filed as
an exhibit to this report and which is incorporated by reference herein.


<P align="left" style="font-size: 10pt">Hextend&#174; and PentaLyte&#174; are registered trademarks of BioTime, Inc.



<P align="left" style="font-size: 10pt"><B>Section&nbsp;9-Financial Statements and Exhibits</B>


<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Exhibit<BR>
Numbers</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><B>Description</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><HR size="1" noshade><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hextend and PentaLyte Collaboration Agreement Between
BioTime, Inc. and Summit Pharmaceuticals International
Corporation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 " SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>BIOTIME, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>Date: December 30, 2004&nbsp;</TD>
    <TD align="left">By</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">&nbsp;/s/ Steven Seinberg
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Steven Seinberg,&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">5
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Exhibit<BR>
Numbers</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><B>Description</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><HR size="1" noshade><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hextend and PentaLyte Collaboration Agreement Between
BioTime, Inc. and Summit Pharmaceuticals International
Corporation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">6
</DIV>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f04328exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt">Exhibit&nbsp;99.1



<P align="center" style="font-size: 10pt">HEXTEND AND PENTALYTE COLLABORATION AGREEMENT BETWEEN<BR>
BIOTIME, INC. AND SUMMIT PHARMACEUTICALS INTERNATIONAL CORPORATION



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following are the terms, under which Summit Pharmaceuticals
International Corporation, a corporation having its principal place of business
at Confort Yasuda Bldg. 2-9, Kanda Nishiki-cho, Chiyoda-ku, Tokyo 101-0054,
Japan (&#147;Summit&#148;), and BioTime, Inc., a California corporation having its
principal place of business at 935 Pardee Street, Berkeley, California
(&#147;BioTime&#148;), intend to collaborate to obtain regulatory approval for the
marketing, sale, and use of BioTime products, Hextend and PentaLyte, for
certain human therapeutic uses in Japan.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Definitions.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#147;Confidential Information&#148; means any information including, but not
limited to, ideas, proposals, plans, know-how, reports, drawings, designs,
data, discoveries, inventions, improvements, suggestions, specifications,
products, samples, components and materials relating to a Product, and all
information relating to the manufacture, formulation, analysis, stability,
pharmacology, toxicology, pathology, clinical data, results of clinical
efficacy studies, clinical effects and indications for use of a Product which a
party discloses to the other party, except any portion thereof which:


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;is known to the receiving party at the time of disclosure and
documented by written records made prior to the date of this Agreement;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;is disclosed to the receiving party by a Third Person who has a right
to make such disclosure;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;becomes patented, published or otherwise part of the public domain
as a result of acts by a third party through no fault of the receiving party
or any subsidiary or other affiliate of the receiving party; or


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;is independently developed by the receiving party without the use of
Confidential Information, as evidenced by its written records.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&#147;Field&#148; means the use of Hextend and PentaLyte in the treatment of
hypovolemia when plasma volume expansion is desired in surgical, trauma care,
or therapeutic procedures and other related or suitable diseases or conditions,
but only for use at body temperatures above 12 Centigrade.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&#147;Hextend&#148; means 6% hetastarch in lactated electrolyte injection, in
the formulation shown on Exhibit&nbsp;A, developed by BioTime as a proprietary
plasma volume expander for the treatment of hypovolemia.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&#147;PentaLyte&#148; means 6% pentastarch in lactated electrolyte injection, in
the formulation shown on Exhibit&nbsp;A, developed by BioTime as a proprietary
plasma volume expander for the treatment of hypovolemia especially for use when
a faster elimination of the starch component is desired and acceptable.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&#147;Product(s)&#148; means Hextend and PentaLyte.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&#147;Regulatory Approval&#148; means, with respect to each Product, any and all
government approvals required to market and use that Product in the Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&#147;Territory&#148; means Japan.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Regulatory Approval For Human Therapeutic Use.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Summit will apply for Regulatory Approval of the Products for use in
the Field. All applications and all laboratory and clinical studies required to
obtain Regulatory Approval of each Product will be conducted by Summit in
accordance with the laws of Japan. These trials will include adequate numbers
of patients to gain Regulatory Approval for the indications in the Field
chosen. Summit will bear all costs associated with these trials.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Summit will fund all laboratory, preclinical and clinical testing and
developmental activities regarding the Products, and will pay all application
filing and similar fees for purposes of obtaining and maintaining Regulatory
Approvals in the Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If BioTime has information concerning the Products that is required by
Japan regulatory agencies for Regulatory Approval of the Products in the Field,
BioTime will share that information with Summit free of charge. BioTime will
only provide Summit with information that BioTime owns and has access to, or
that BioTime has access to and permission from any third party owners to
disclose to Summit.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Although BioTime plans to conduct additional clinical studies of
PentaLyte in the United States, and may conduct additional clinical and
laboratory studies of Hextend for markets other than the Territory, BioTime
will not be under any obligation to conduct any further clinical trials or
laboratory studies of the Products for Regulatory Approval in the Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;BioTime will provide Summit with quantities of the Products for use in
clinical and laboratory studies required to obtain Regulatory Approval in the
Territory. The price payable to BioTime for the Products so supplied shall be
equal to BioTime&#146;s cost of purchasing and delivering the Product to Summit.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;BioTime will have non-exclusive access to, and use of, all clinical
and laboratory study data and other data and information generated by Summit or
others from the clinical testing, laboratory testing, and Regulatory Approval
of the Products in the Territory.


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;After this Agreement is executed, BioTime will provide or make
available to Summit at BioTime&#146;s offices, BioTime&#146;s information concerning
Hextend that BioTime has agreed to share with Summit in paragraph 2(c), to the
extent that Summit requests such information. Summit shall prepare a plan for
obtaining Regulatory Approval of Hextend in the Territory, including but not
limited to designing such clinical and laboratory studies as may be required,
selecting the hospitals at which clinical studies will be conducted, selecting
the physicians who will be the lead investigators for the clinical studies, and
selecting the statistical analysts who will prepare reports of the outcome of
the clinical studies (the &#147;Development Plan&#148;). The Development Plan will be
based upon information obtained by Summit from BioTime and from Summit&#146;s
consultations with doctors and other medical advisors, hospital administrators,
and representatives of government agencies from which Regulatory Approval must
be obtained. The Development Plan will include a timetable for commencing and
completing clinical trials, preparing and submitting an application for
Regulatory Approval, and obtaining Regulatory Approval of Hextend in the
Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Within six months after this Agreement is signed by the parties,
Summit shall submit the Development Plan to BioTime for BioTime&#146;s review and
approval. BioTime shall have the right to recommend or request changes to the
Development Plan, but will not unreasonably delay or withhold its consent to
the Development Plan.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Summit will commence seeking Regulatory Approval of Hextend
(including designing, arranging, and conducting any and all clinical and
laboratory studies) promptly after the Development Plan is completed and
approved by BioTime. Summit shall use commercially reasonable and diligent
efforts to complete all clinical and laboratory studies and to file all
applications, reports, and documents, and shall pay all filing fees and other
fees required to obtain Regulatory Approval of Hextend in the Territory within
the Development Plan timetable. BioTime and Summit shall agree upon a time
schedule for Summit to conduct seek and obtain Regulatory Approval for
PentaLyte in the Territory (including clinical and laboratory studies), but
Summit shall not be obligated to commence such efforts with respect to
PentaLyte until the results of BioTime&#146;s phase II clinical study of PentaLyte
in the United States have been disclosed to Summit.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Summit shall send BioTime written progress reports every six months
after the Development Plan is approved. The progress reports will summarize in
reasonable detail the work performed by Summit and the results of such work
under the Development Plan during the period covered. Each progress report
shall include in reasonable detail any proposed changes to the Development Plan
or the Development Plan timetable. Summit&#146;s progress reports will include
copies of correspondence with regulatory authorities and, to the extent
available, data obtained from clinical studies. If BioTime requests additional
information concerning any progress report or the actions taken by Summit under
the Development Plan, Summit will provide such information within two weeks.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Summit shall not make any changes to the Development Plan without
BioTime&#146;s consent, which consent shall not be unreasonably withheld, provided
that the changes are
suggested by Summit in good faith for the purpose of obtaining Regulatory
Approval of Hextend in an expeditious and commercially reasonable and medically
prudent manner.


<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;Summit shall promptly notify BioTime of (A)&nbsp;any communication from any
government authority concerning clinical trials or Regulatory Approval, and (B)
any adverse outcomes in clinical trials or other developments that could
reasonably warrant a change in the Development Plan or could result in a
material delay in implementing or completing any aspect of the Development
Plan.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Manufacturing and Marketing.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;BioTime and Summit shall collaborate to find an appropriate licensee
to manufacture and market a Product in the Territory in the late development
stages or for marketing. Summit shall inform BioTime of its wishes to commence
searching together for a licensee, but in no event later than the NDA (or
Japanese equivalent) filings of Hextend and PentaLyte, respectively, in the
Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This Agreement does not grant to Summit a license to use BioTime
patents or technology to manufacture, have manufactured, market, or sell any
Product. Any such licenses shall be granted only to a licensee mutually
acceptable to BioTime and Summit.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Patents. Summit shall cooperate with BioTime in filing patent
applications in the Territory. Any patent rights to any modification of any
Product or any other product or technology developed by BioTime shall belong to
BioTime. Summit shall cooperate with BioTime in filing and prosecuting patent
applications in BioTime&#146;s name covering such modifications or technology.
Summit shall not use any Product, any of BioTime&#146;s technology (patented or
unpatented) or any of BioTime&#146;s Confidential Information to develop and patent
(including filing for any patent protection or registration) any technology
other than in the name of BioTime.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;Payments.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Summit will make the following payments to BioTime:


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Three hundred thousand US dollars
($300,000) within ten (10)&nbsp;days after execution of this
Agreement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Four hundred fifty thousand US
dollars ($450,000) by April&nbsp;15, 2005.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;One hundred fifty thousand US
dollars ($150,000) by October&nbsp;31, 2005.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The cash payment described in (i)&nbsp;and one-half of the cash payment
described in (ii)&nbsp;of paragraph (a)&nbsp;of this Section shall be a partial
reimbursement of BioTime&#146;s development costs of Hextend. The cash payments
described in (iii)&nbsp;and one-half of the cash payment described in (ii)&nbsp;of
paragraph (a)&nbsp;of this Section shall be a partial reimbursement of BioTime&#146;s
development costs of PentaLyte.


<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Within ten (10)&nbsp;days after approving the Development Plan, BioTime
shall pay Summit a one-time fee of One Hundred Thirty Thousand Dollars
($130,000) for Summit&#146;s services in preparing the Development Plan.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Revenue Sharing.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Summit may sublicense a portion of its rights for the co-development
and/or marketing of the Products in the Territory, provided, that after any
such sublicense (i)&nbsp;Summit and BioTime together retain effective power to make
all decisions that, without any such sublicense, would be made by Summit and
BioTime together, (ii)&nbsp;Summit rather than any assignee, licensee or sublicense
of Summit will retain any and all power and authority that Summit may have to
make any determinations and agreements, and to give or withhold any approvals,
that may arise under its agreement with BioTime, such that (A)&nbsp;BioTime may deal
directly and exclusively with Summit, (B)&nbsp;Summit shall not have delegated its
powers and authority under its agreements with BioTime, and (C)&nbsp;any such
determination, agreement, or approval by Summit shall be binding on its
assignees, licensees or sublicensees, and (iii)&nbsp;BioTime retains the right and
power to enforce its rights as licensor and to enforce the obligations of the
licensee under any license granted by BioTime. In the event the potential
co-development sublicensee requests marketing and or sale rights, as well,
Summit shall inform BioTime and shall decide to appoint such sublicensee only
after obtaining the consent of BioTime.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;When the Products are licensed and sold in the Territory, the revenues
from licensing fees, royalties, and net sales, and any other payments made for
the right to co-develop with Summit, manufacture, market, or sell any of the
Products in the Territory, shall be shared between BioTime and Summit as
follows: 40% to BioTime and 60% to Summit. Net sales means the gross revenues
from the sale of a Product, less rebates, discounts, returns, transportation
costs, sales taxes and import/export duties.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;BioTime will pay to Summit 8% of all net royalties actually received
by BioTime from the sale of PentaLyte in the United States plus 8% of any
license fees that BioTime receives in consideration of granting a license to
develop, manufacture and market PentaLyte in the United States. Net royalties
means royalty payments received during a calendar year, minus the following
costs and expenses incurred during such calendar year: (a)&nbsp;all taxes assessed
(other than taxes determined with reference to BioTime net income) and credits
given or owed by BioTime in connection with the receipt of royalties on the
sale of PentaLyte in the United States, and (b)&nbsp;all fees and expenses payable
by BioTime to the United States Food and Drug Administration (directly or as a
reimbursement of any licensee) with respect to a PentaLyte. In the case of
license fees received from Hospira, Inc. based upon the combined sale of
PentaLyte and Hextend, the portion of such license fee that will be deemed to
be a paid on account of the sale of PentaLyte will be determined by multiplying
the total license fee paid by a fraction, the numerator of which will be the
total net sales of PentaLyte in the United States for the applicable period and
the denominator of which shall be the total net sales of Hextend and PentaLyte
in the United States for the same period.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Confidentiality. Neither party shall disclose any Confidential
Information received



<P align="center" style="font-size: 10pt">5
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">from the other party pursuant this Agreement. This obligation will
continue for a period of ten (10)&nbsp;years after expiration or prior termination
of this Agreement. Nothing contained in this Section shall be construed to
restrict the parties from disclosing Confidential Information as required:



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;For regulatory, tax or customs reasons;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;For audit purposes;


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;By court order or other government order or request as long as
reasonable efforts have been made to assure its confidentiality or BioTime is
timely notified to make such efforts; or


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;For using such Confidential Information as is reasonably necessary to
perform acts permitted by this Agreement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;Indemnification. Summit shall defend, indemnify and hold BioTime
harmless against any liability, damage, loss, cost or expense, including legal
fees, arising out of or resulting from any claims or lawsuits made or brought
against BioTime to the extent such damage, loss, cost or expense arises out of
or relates to negligence or willful misconduct of Summit or any subsidiary or
third party with regard to the use, testing, storage of, or other action or
omission with respect to, a Product, including the injury or death of any
patient during any clinical trial conducted by or for Summit in the Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;Termination.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Either party may terminate this Agreement as follows:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="9%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By giving to the other party sixty
(60)&nbsp;days prior written notice following the bankruptcy
or the insolvency of the other party.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="9%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the breach of any material
provision of this Agreement by the other party if the
breach is not cured within sixty (60)&nbsp;days after written
notice thereof to the party in default; or</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;BioTime may terminate this Agreement upon sixty (60)&nbsp;days prior
written notice at any time following Summit&#146;s failure to use diligent efforts
to achieve any one of the following milestones: (A)&nbsp;submitting to BioTime for
approval a Development Plan that is substantially complete in all material
respects within six months after the parties sign this Agreement, (B)
initiating and conducting to completion clinical studies needed for Regulatory
Approval of at least one Product in the Territory in accordance with the
timetable included in the Development Plan approved by BioTime; or (C)
obtaining Regulatory Approval of at least one Product in the Territory after
the clinical studies are complete. If BioTime gives Summit notice of
termination under this paragraph and Summit disputes the factual basis for
terminating this Agreement, the dispute shall be resolved in the manner
provided in Section&nbsp;11.


<P align="center" style="font-size: 10pt">6
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Summit may terminate this Agreement at any time upon ninety (90)&nbsp;days
prior written notice to BioTime if Summit determines that it no longer wishes
to pursue obtaining Regulatory Approval of at least one Product in the
Territory.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Termination, expiration, cancellation or abandonment of this Agreement
through any means and for any reason shall not relieve the parties of any
obligation accruing prior thereto and shall be without prejudice to the rights
and remedies of either party with respect to any antecedent breach of any of
the provisions of this Agreement, and provisions of Section&nbsp;8 of this Agreement
shall survive termination of this Agreement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Upon termination of this Agreement, Summit and each of its assignees,
if any, shall promptly return to BioTime all copies of BioTime&#146;s Confidential
Information, and BioTime shall return to Summit all copies of all of Summit&#146;s
Confidential Information, except that (i)&nbsp;BioTime shall have a right to retain
and use outside the Territory all of Summit&#146;s Confidential Information if this
Agreement is terminated for any reason other than a termination by Summit under
paragraph (c)&nbsp;above, and (ii)&nbsp;if Summit terminates this Agreement under
paragraph (c)&nbsp;above, BioTime may retain and use all Summit Confidential
Information inside or outside the Territory in connection with the development,
Regulatory Approval, manufacture, marketing, and sale of the Products.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Upon the expiration or termination of this Agreement, Summit shall
immediately cease all use of all Products and BioTime Confidential Information,
and shall discontinue all laboratory and clinical testing of the Products. If
Summit terminates this Agreement under paragraph (c)&nbsp;above, Summit shall
execute all documents necessary to assign to BioTime all of Summits rights with
respect to Regulatory Approval, including but not limited to all applications,
approvals, and permits.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Notwithstanding the contents of paragraph (f)&nbsp;above, upon the
occurrence of an event giving Summit the right to terminate this Agreement in
accordance with paragraph (a), Summit may elect to keep this Agreement in
effect, and in lieu of any other remedy that Summit might have (1)&nbsp;Summit shall
be exempted from the remaining payments described in Section&nbsp;5(a), if any, and
(2)&nbsp;the 40% share of revenue of BioTime described in Section 6(b) shall be
reduced to 20%.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;Governing Law. This Agreement shall be construed under and governed
by California law without regard to conflicts of interest principles or the
choice of law principles of California or any other jurisdiction.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Dispute Resolution.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The parties recognize that bona fide disputes may arise which relate
to the parties&#146; rights and obligations under this Agreement. The parties agree
that any such dispute shall be resolved by arbitration. Arbitration shall be
held in San Francisco, California according to the commercial rules of the
American Arbitration Association (&#147;AAA&#148;) provided, however, that the parties
shall be entitled to take depositions and obtain discovery as provided in
California Code of Civil Procedure Section&nbsp;1283.05, and the arbitrator or
arbitrators shall have the powers as set forth


<P align="center" style="font-size: 10pt">7
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="left" style="font-size: 10pt">therein. In addition, the arbitrators shall have the authority to impose
sanctions for the failure or refusal of any party to permit discovery as
provided in California Code of Civil Procedure Section&nbsp;1283.05 or to comply
with any discovery order of the arbitrators. Such sanctions against a party
may include, without limitation, one or more of the following: (i)&nbsp;inference
that facts alleged by the adverse party are true and correct; (ii)&nbsp;a
prohibition or limitation upon the evidence that may be presented by the party
being sanctioned; (iii)&nbsp;the entry of a default award in against the party being
sanctioned and in favor of the adverse party, and (iv)&nbsp;the imposition or
assessment of costs and attorneys&#146; fees against the party being sanctioned.
The arbitration will be conducted by a panel of three (3)&nbsp;arbitrators appointed
in accordance with AAA rules; provided, however, that each party shall within
thirty (30)&nbsp;days after the institution of the arbitration proceedings appoint
an arbitrator, and the two arbitrators so appointed shall select a neutral
arbitrator to be the chairman of the arbitration panel, within thirty (30)&nbsp;days
thereafter. If the arbitrators appointed by the parties are unable to select a
neutral arbitrator within such thirty (30)&nbsp;day period, the neutral arbitrator
shall be appointed in accordance with the AAA rules. All arbitrators eligible
to conduct the arbitration must agree to render their opinion(s),
determination(s) and award(s) within thirty (30)&nbsp;days after the final
arbitration hearing.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither any individual arbitrator nor the panel of arbitrators shall
have the power to award punitive damages under this Agreement, and any award of
punitive damages is expressly prohibited. Decisions of the arbitrators shall be
final and binding upon the parties. Judgment on the arbitration award rendered
by the arbitrators may be entered in a court having jurisdiction. In any
arbitration pursuant to this Agreement, the arbitrators shall apply the
substantive laws of the state of California. Summit agrees to submit to the
jurisdiction of the courts of the state of California.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;Counterparts; Electronic Signatures. This Agreement may be executed
in two or more counterparts, each of which shall be an original and together
which shall constitute one and the same instrument. This Agreement may be
executed by facsimile or other electronic signature. If a party provides a
facsimile or electronic signature, that party shall also promptly send the
other party a manually signed paper copy of this Agreement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;Notices. All notices given under this Agreement shall be in writing
and shall be delivered personally, by facsimile confirmed by postage prepaid
first-class mail, by over-night or next business day air courier, or by postage
prepaid certified mail to the following addresses of the respective parties:


<P align="center" style="font-size: 10pt">8
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="9%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Summit Pharmaceuticals International Corporation<br>
Confort Yasuda Building 2-9<br>
Kanda Nishiki-cho,<br>
Chiyoda-ku, Tokyo 101-0054<br>
Facsimile: 81 (03)&nbsp;3294-1614<br>
Attention: President
<br>
<br></TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="9%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>BioTime, Inc.<br>
935 Pardee Street<br>
Berkeley, California 94710<br>
Facsimile: (510)&nbsp;845-7914<br>
Attention: Hal Sternberg, Vice President<br>
With copies to: Chief Financial Officer</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt">Notices shall be effective upon receipt if personally delivered or delivered by
facsimile or air courier, or on the fifth business day following the date of
mailing. A party may change its address listed above by notice to the other
party.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;Assignment; Sublicense. Neither party shall assign this Agreement or
any part thereof without the prior written consent of the other party;
provided, however, that without the consent of the other party (a)&nbsp;Summit may
assign this Agreement to a wholly-owned subsidiary of Summit, but such
assignment shall not relieve Summit of responsibility for the performance of
all of the obligations which it assigns, (b)&nbsp;BioTime may assign this Agreement
to a wholly owned subsidiary of BioTime, (c)&nbsp;BioTime may assign its rights to
receive payments, and (d)&nbsp;BioTime may assign or sell its rights and obligations
under this Agreement in connection with the transfer or sale of substantially
its entire business to which this Agreement pertains or through a merger or
consolidation with another company. Any permitted assignee (other than an
assignee of a right to receive payments due BioTime) shall assume all
obligations of its assignor under this Agreement. No assignment shall relieve
any party of responsibility for the performance of any obligation which such
party has hereunder.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;Entire Agreement. This Agreement and the Exhibits constitute the
entire agreement between the parties concerning the subject matter hereof and
supersede all written or oral prior agreements or understandings with respect
thereto. No course of dealing or usage of trade shall be used to modify the
terms and conditions hereof.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;Severability. This Agreement is subject to the restrictions,
limitations, terms and conditions of all applicable laws, governmental
regulations, approvals and clearances. If any term or provision of this
Agreement shall for any reason be held invalid, illegal or unenforceable in any
respect, such invalid, illegal or unenforceable provision shall be modified so
as to conform to the applicable requirements, and this Agreement shall be
modified by the parties so as to accomplish as nearly as possible the original
intention of the parties consistent with applicable laws and regulations.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;Waiver
- - Modification of Agreement. No waiver or modification of any
of the terms of this Agreement shall be valid unless in writing and signed by
authorized representatives of the party to be charged. Failure or delay by
either party to enforce any rights under this Agreement shall not be


<P align="center" style="font-size: 10pt">9
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="left" style="font-size: 10pt">construed as a waiver of such rights nor shall a waiver by either party in
one or more instances be construed as constituting a continuing waiver or as a
waiver in other instances.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;Press Release. BioTime and Summit each agrees that the other party
may issue a press release concerning the entering into of this Agreement, with
the content of such press releases to be approved by the non-issuing party
(which consent shall not be unreasonably withheld or delayed).

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">SUMMIT PHARMACEUTICALS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">BIOTIME, INC.</TD>
</TR>

<TR valign="bottom">

<TD valign="top" colspan="9"><DIV style="margin-left:0px; text-indent:-0px">INTERNATIONAL CORPORATION
</DIV></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Masahiro Sasaki
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Hal Sternberg</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Masahiro Sasaki
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hal Sternberg</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">V.P.; Office of the President</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Date: December&nbsp;24, 2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date: December&nbsp;21, 2004</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">10
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt">BIOTIME, INC.<BR>
AND<BR>
SUMMIT PHARMACEUTICALS INTERNATIONAL CORPORATION



<P align="center" style="font-size: 10pt">EXHIBIT A



<P align="center" style="font-size: 10pt">Product Formulation



<P align="center" style="font-size: 10pt">Hextend and PentaLyte Formulation



<P align="left" style="font-size: 10pt">Hydroxyethyl Starch 6%<br><br>
Sodium Chloride 115 millimoles/liter<br><br>
Magnesium Chloride Hexahydrate 0.45 millimoles/liter<br><br>
Calcium Chloride Dihydrate 2.5 millimoles/liter<br><br>
Potassium Chloride 3 millimoles/liter<br><br>
Glucose 5 millimoles/liter<br><br>
Sodium Lactate 28 millimoles/liter



<P align="center" style="font-size: 10pt">11
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
